Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 4Recruiting 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Neoplasms 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × enfortumab vedotin × Clear all
NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

ALX Oncology Inc.

Phase 1 Completed
36 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Inc

Phase 1 Completed
213 enrolled
GenitourinaryOther solid neoplasm

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

NCT03070990 2024-10-18

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Astellas Pharma Inc

Phase 1 Completed
19 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT01409135 2024-03-12

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Inc

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡